Macmiror, 200 mg 20 pcs

Macmiror is an antimicrobial, antiprotozoal, antifungal.

Pharmacodynamics

Nifuratel, antimicrobial agent of the nitrofuran group; has antiprotozoal, antifungal and antibacterial action.

Nifuratel has high efficacy and low toxicity, which leads to a wide range of its clinical use.

Highly effective against Papiliobacter and Helicobacter pylori, Gram-positive and Gram-negative microorganisms: at minimum inhibitory concentration (MIC) of 12.5-25 µg/ml it suppresses from 44.3 to 93.2% of cultures.

High activity against both aerobic and anaerobic pathogens.

The spectrum of action includes: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Shigella flexneri 2a, Shigella flexneri 6, Shigella sonnei, Salmonella typhi, Salmonella typhimurium, Salmonella enteritidis, Klebsiella spp, Enterobacter spp., Serratia spp, Citrobacter spp., Morganella spp., Rettgerella spp., Pragia fontium, Budvicia aquatica, Rachnella aquatilis and Acinetobacter spp., other atypical Enterobacteriaceae as well as protozoa (amebas, giardia); less active against Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa.

It is the drug of choice for the treatment of salmonellosis, shigellosis and other intestinal bacterial infections.

It is active against Trichomonas vaginalis, highly active against fungi of the genus Candida.

It is particularly effective against strains of Helicobacter pylori that are resistant to metronidazole.

There is evidence of high activity of nifuratel (in vitro and in vivo) against Atopobium vaginae, the main marker of bacterial vaginosis.

Pharmacokinetics

In oral administration, it is rapidly absorbed from the gastrointestinal tract. It penetrates through the BBB and the blood-placental barrier and is excreted with breast milk. It is metabolized in the liver and muscle tissue. It is completely excreted by kidneys (30-50% – unchanged), having strong antibacterial effect in the urinary tract.

Indications

vulvovaginal infections caused by pathogens sensitive to the drug (pathogenic microorganisms, candida, trichomonas, bacteria, chlamydia);
chronic inflammatory diseases of the upper gastrointestinal tract associated with Helicobacter pylori (chronic gastritis, gastric and duodenal ulcers, gastroesophageal reflux disease);
intestinal amebiasis and giardiasis;
pyelonephritis, urethritis, cystitis, pyelitis and other diseases of the urinary system.

Pharmacological effect

Macmiror – antimicrobial, antiprotozoal, antifungal.

Pharmacodynamics

Nifuratel, an antimicrobial agent from the nitrofuran group; has antiprotozoal, antifungal and antibacterial effects.

Nifuratel has high efficiency and low toxicity, which determines a wide range of its clinical use.

Highly effective against Papiliobacter and Helicobacter pylori, gram-positive and gram-negative microorganisms: at a minimum inhibitory concentration (MIC) of 12.5–25 μg/ml, it suppresses from 44.3 to 93.2% of cultures.

Shows high activity against both aerobic and anaerobic pathogens.

The spectrum of action includes: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Shigella flexneri 2a, Shigella flexneri 6, Shigella sonnei, Salmonella typhi, Salmonella typhimurium, Salmonella enteritidis, Klebsiella spp., Enterobacter sph., Serratia spp., Citrobacter spp., Morganella spp., Rettgerella spp., Pragia fontium, Budvicia aquatica, Rachnella aquatilis and Acinetobacter spp., other atypical enterobacteria, as well as protozoa (amoebas, lamblia); less active against Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa.

It is the drug of choice for the treatment of salmonellosis, shigellosis and other intestinal bacterial infections.

Active against Trichomonas vaginalis, highly active against fungi of the genus Candida.

Particularly effective against Helicobacter pylori strains resistant to metronidazole.

Data have been obtained indicating the high activity of nifuratel (in vitro and in vivo) against Atopobium vaginae, the main marker of bacterial vaginosis.

Pharmacokinetics

When taken orally, it is quickly absorbed from the gastrointestinal tract. Penetrates the blood-brain barrier and the hematoplacental barrier and is excreted in breast milk. Metabolized in the liver and muscle tissue. It is completely excreted from the body by the kidneys (30–50% unchanged), providing a strong antibacterial effect in the urinary tract.

Special instructions

When monotherapy for vaginal infections with Macmiror, it is recommended to increase the daily dosage to 4–6 tablets. During the treatment period you should abstain from sexual intercourse.

Impact on the ability to drive a car or use other machinery: no negative effects have been identified.

Active ingredient

Nifuratel

Composition

Active ingredient:

nifuratel 200 mg;

Auxiliary ingredients:

starch;

polyethylene glycol 6000;

talc;

magnesium stearate;

gelatin;

gum arabic;

sucrose;

magnesium carbonate;

titanium dioxide;

E wax;

Contraindications

Hypersensitivity to the active substance or any component of the drug.

Side Effects

Dyspeptic disorders: nausea, vomiting, bitterness in the mouth, diarrhea, heartburn, gastralgia.

Allergic reactions: skin rash, itching.

Interaction

Strengthens the antifungal effect of nystatin.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

5 years

Manufacturer

Doppel Pharmaceutici S.R.L., Italy